Long-term response to crizotinib in a 17-year-old boy with treatment-naïve ALK-positive non-small-cell lung cancer.

Giacomina Megaro Evelina MieleGian Paolo SpinelliIside AlessiGiada Del BaldoRaffaele CozzaIda RussoMaria Debora De PasqualeMaria Giuseppina CefaloPaolo TomàAndrea CaraiValentina Di RuscioMaria Antonietta De IorisAngela Mastronuzzi

Published in: Cancer reports (Hoboken, N.J.) (2022)

Crizotinib can be extremely effective in adolescents with treatment-naïve ALK-positive NSCLC but fail to prevent a central nervous system relapse. Resistance mechanisms need to be investigated.

Keyphrases

advanced non small cell lung cancer
epidermal growth factor receptor
mass spectrometry
high resolution
cerebrospinal fluid
high speed